软组织肉瘤Ki-67和EGFR及PDGFR表达与预后相关性分析

Clinical value of expressions of Ki-67,EGFR and PDGFR in predicting prognosis of soft tissue sarcoma

目的:探讨软组织肉瘤中增殖细胞核抗原Ki-67、EGFR和PDGFR表达状况对判断预后的临床价值。方法:免疫组化法检测60例软组织肉瘤患者瘤体组织Ki-67、EGFR和PDGFR的表达水平,结合短期随访观察Ki-67、EGFR和PDG-FR不同表达的患者总生存率和复发率的差异。结果:Ki-67阴性表达患者第1年和第2年总生存率分别为100.0%和95.5%,均高于阳性表达患者的83.9%和76.0%;Ki-67阴性表达患者第1年和第2年复发率分别为6.9%和8.3%,高于阳性表达患者的22.6%和48.0%。EGFR与Ki-67均为阳性表达与均为阴性表达的患者,第1、2年的总生存率差异无统计学意义,P>0.05;PDGFR与Ki-67均为阳性表达与均为阴性表达的患者,第1、2年的总生存率差异无统计学意义,P>0.05。结论:增殖细胞核抗原Ki-67在软组织肉瘤中阳性表达提示预后不良,增加EGFR、PDGFR与Ki-67进行双指标检测并未提高预测的敏感性。

OBJECTIVE： To evaluate the values of expression of Ki-67,EGFR and PDGFR in predicting prognosis progression of soft tissue sarcoma. METHODS： Ki-67,EGFR and PDGFR protein express prognosis levels of the biopsy tissues were detected in 60 patients with soft tissue sarcoma. The relationship between Ki-67 ,EGFR and PDGFR protein expressions and prognosis were analyzed combined with short-term follow-up. RESULTS： The overall survival rate of pa- tients with Ki 67 low expression in the first year and the second year were 100.0 % and 95.5 % respectively, which were better than that of the patients with Ki-67 over expression （83.9%,76.0%）;The recurrence rate of patients with Ki-67 low expression in the first year and the second year were 6.9% and 8.3% respectively,which was better than that of the patients with Ki-67 over expression （22.6% ,48.0%）. There was no difference between the patients with low expression level of Ki-67 and EGFR and over expression in overall survival rate （P〉0. 05） ;There was no difference between the pa- tients with low expression level of Ki-67 and PDGFR and over expression in overall survival rate（P〉0.05）. CONCLU- SION： Ki-67 immunoreactivities are predictive of soft tissue sarcoma prognosis, and predictive value is not improved by combination detecting EGFR and PDGFR.